Notice of Results
1 August 2014
("Instem" or the "Company")
Notice of Results
Instem plc (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, will be announcing its unaudited interim results for the six months ended 30 June 2014 on Wednesday 24th September.
Management will be hosting a presentation for analysts on the day of results at 09:30am at the offices of N+1 Singer, One Bartholomew Lane, London, EC2N 2AX.
If you wish to attend, or require further information, please contact Bob Huxford or Sam Allen at Walbrook PR on 020 7933 8780 or email firstname.lastname@example.org to register.
For further information, please contact:
|Phil Reason, CEO||+44 (0) 1785 825600|
|Nigel Goldsmith, CFO|
|N+1 Singer (Nominated Adviser & Broker)||+44 (0) 20 7496 3000|
|Wallbrook Financial PR||Tel: +44 (0) 20 7933 8000|
|Paul Cornelius||or email@example.com|
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.
To learn more about Instem solutions and its mission, please visit instem.com.